Valuation : Infant Bacterial Therapeutics AB

Market Cap 857M 88.42M 76.19M 72.14M 65.39M 123M 8.45B 123M 329M 4.3B 332M 325M 13.58B P/E 2024
-5.27x
P/E 2025 -10.4x
Enterprise Value 713M 73.56M 63.38M 60.01M 54.4M 102M 7.03B 103M 274M 3.58B 276M 270M 11.3B EV / Sales 2024
124,670,028,000x
EV / Sales 2025 -
Free-Float
82.6%
Yield 2024 *
-
Yield 2025 -
1 day-0.93%
1 week-2.15%
Current month-0.78%
1 month-2.15%
3 months+6.00%
6 months+29.80%
Current year+25.94%
1 week 63
Extreme 63
66
1 month 60.7
Extreme 60.7
73.7
Current year 44.75
Extreme 44.75
73.7
1 year 43.25
Extreme 43.25
74
3 years 21.7
Extreme 21.7
135
5 years 21.7
Extreme 21.7
135
10 years 21.7
Extreme 21.7
274.5
Manager TitleAgeSince
Chief Executive Officer 59 2012-12-31
Director of Finance/CFO 53 2022-09-18
Chief Tech/Sci/R&D Officer 70 -
Director TitleAgeSince
Chairman 76 2010-12-31
Director/Board Member 60 2015-09-23
Director/Board Member 60 2017-05-03
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/25 Free

Chief Executive Officer

65,000 0.4993%
9/25/25 Free

Chief Operating Officer

32,500 0.2497%
9/25/25 Free

Chief Financial Officer

32,500 0.2497%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-2.15%-14.40%-26.39% 88.42M
-0.54%-4.26%+69.03%+32.53% 355B
-0.15%-3.24%+21.83%-20.33% 66.33B
+0.19%-2.71%+38.27%+185.87% 12.17B
-0.66%-8.82%-11.70%-16.24% 7.47B
-4.80%-8.31%-28.14%-8.74% 4.64B
+0.63%-2.46%-33.22%+4.34% 4.42B
-1.24%-6.98%-34.91%-13.14% 2.86B
-0.12%-4.34%-10.76%+39.83% 2.42B
-1.84%-5.00%-28.35%-23.61% 1.9B
Average -0.95%-4.36%-3.24%+15.41% 45.74B
Weighted average by Cap. -0.51%-4.15%+56.58%+26.97%

Financials

2024 2025
Net sales 0 0 0 0 0 0 0.04 0 0 0.02 0 0 0.06 -
Net income -137M -14.13M -12.17M -11.53M -10.45M -19.6M -1.35B -19.7M -52.65M -687M -53.06M -51.9M -2.17B -65.17M -6.73M -5.79M -5.49M -4.97M -9.33M -643M -9.38M -25.06M -327M -25.26M -24.7M -1.03B
Net Debt -223M -23.05M -19.86M -18.81M -17.05M -31.98M -2.2B -32.15M -85.9M -1.12B -86.58M -84.69M -3.54B -144M -14.86M -12.81M -12.13M -10.99M -20.62M -1.42B -20.72M -55.38M -722M -55.82M -54.59M -2.28B
Logo Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Employees
6
Date Price Change Volume
26-09-11 SEK 63.60 -0.93% 11,651
26-09-10 SEK 64.20 -0.77% 6,286
26-09-09 SEK 64.70 +1.25% 1,054
26-09-08 SEK 63.90 -0.31% 9,304
26-09-07 SEK 64.10 -1.38% 3,006
  1. Stock Market
  2. Stocks
  3. IBT B Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!